Skip to main content
. Author manuscript; available in PMC: 2017 Feb 27.
Published in final edited form as: Nat Commun. 2015 Sep 1;6:8126. doi: 10.1038/ncomms9126

Figure 3. Regulation of YAP1 and AR interactions by antiandrogen in vitro.

Figure 3

(a,b) Co-IP and WB analysis of AR and YAP1 proteins in cytoplasmic and nuclear fractions obtained (a) from LNCaP cells that were treat with DMSO, enzalutamide (ENZ) plus or mice DHT or (b) from C4-2 cells that were treated with DMSO or enzalutamide without DHT exposure. (c) Analysis of LNCaP or C4-2 cell growth after treatment with DMSO or enzalutamide without DHT in vitro; *P<0.001. (d) Co-IP and WB analysis of AR and YAP1 proteins in cytoplasmic and nuclear fractions obtained from LNCaP cells with or without MST1 knockdown plus or minus DHT treatment. Co-IP and WB were probed with antibodies to corresponding proteins at 24 in experiment (a,b) and at 48 h in experiment ‘d’ post treatment. Lamin A/C was used as a nuclear extraction control. Blots are representative of two independent experiments. C, Cytoplasm; N, Nuclei. (e) Analysis of LNCaP cell growth with or without MST1 knockdown plus or minus DHT treatment in vitro; *P<0.002. To assess growth, cell viability was determined by MTS assay at 72 h post treatment. Data (±s.e.) in c and e are representation of two independent experiments in triplicates.